ContraFect Corporation (CFRXQ)
Market Cap | 107.05K |
Revenue (ttm) | n/a |
Net Income (ttm) | -24.14M |
Shares Out | 10.70M |
EPS (ttm) | -15.30 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,000 |
Open | 0.0010 |
Previous Close | 0.0120 |
Day's Range | 0.0010 - 0.0100 |
52-Week Range | 0.0010 - 1.3100 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About CFRXQ
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/r/e/press12-2104272.jpg)
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens all...
![](https://cdn.snapi.dev/images/v1/1/4/conf7-2069018.jpg)
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA...
![](https://cdn.snapi.dev/images/v1/s/6/press19-2067010.jpg)
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/b/n/conf16-2039258.jpg)
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/g/t/press7-2021475.jpg)
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/p/t/press4-1949425.jpg)
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/n/k/press5-1940382.jpg)
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/o/1/conf16-1927233.jpg)
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/r/y/press6-1889738.jpg)
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), in...
![](https://cdn.snapi.dev/images/v1/m/t/press19-1854784.jpg)
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/f/l/press14-1845660.jpg)
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/u/9/press5-1828186.jpg)
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa
![](https://cdn.snapi.dev/images/v1/0/a/press3-1822975.jpg)
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA...
![](https://cdn.snapi.dev/images/v1/x/o/press15-1820777.jpg)
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/j/o/press12-1774244.jpg)
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement
YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/f/5/press3-1681212.jpg)
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023 Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023
![](https://cdn.snapi.dev/images/v1/j/1/press18-1673216.jpg)
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/w/5/press4-1652603.jpg)
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/s/5/press13-1634731.jpg)
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies
![](https://cdn.snapi.dev/images/v1/3/n/press18-1539754.jpg)
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/x/r/press20-1539720.jpg)
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
![](https://cdn.snapi.dev/images/v1/m/y/press11-1504714.jpg)
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies
![](https://cdn.snapi.dev/images/v1/w/b/press4-1504695.jpg)
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...
![](https://cdn.snapi.dev/images/v1/h/t/press6-1451297.jpg)
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins...
![](https://cdn.snapi.dev/images/v1/w/j/press20-1415005.jpg)
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect's Direct Lytic Agents (DLAs) to Address MRSA Infections
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA...